By Jenny A | Posted - May 8th, 2019

 

 

 

 

BB2121 CAR T Results Described in New England Journal of Medicine

Last week the New England Journal of Medicine published results from the Phase I Celgene bb2121 CAR T clinical trial. 

In the Phase I study, 33 patients with relapsed or refractory myeloma were giving bb2121 as a single infusion of the CAR T product at different doses in the dose escalation phase (50×106, 150×106, 450×106, or 800×106 ). Two of of those doses (150×106 to 450×106) were used in the expansion phase. Patients who participated had received at least three prior lines of treatment and their myeloma had become resistant to both a proteasome inhibitor and an immunomodulator. As in all phase I studies, the goal is to assess safety. 

The following data was gathered up until 6.2 months after the last patient's infusion date:

  • Most common grade 3 or higher side effects included: neutropenia (85%), leukopenia (58%), anemia (45%) and thrombocytopenia (45%). 
  • Grade 1 or 2 cytokine release syndrome was found in 70% of patients. Grade 3 CRS was found in 6% of patients. 
  • Grade 1 or 2 neurologic toxicity was found in 39% of patients. One patient had a reversible grade 4 neurologic toxic effect.  
  • The objective response rate was 85%. Fifteen patients (45%) had complete responses and six of these 15 have relapsed. 
  • Sixteen patients who had a partial response or better were tested for minimal residual disease (MRD) and had MRD negative status. 
  • The median progression-free survival was 11.8 months.  
  • The CAR T cells persisted up to 1 year after the infusion.

This graph shows each patient, the dose they received and how they have responded over a period of up to 23 months. The patients in this study were heavily pretreated. While median numbers are important, we believe that future work with CAR T cells in multiple myeloma will better identify patients who will respond well and maintain responses to this type of treatment. These are the first and most comprehensive data on CAR T in multiple myeloma to date. 

According to principal investigator Noopur Raje, MD of Massachusetts General Hospital:

“The adverse events noted in our study were very manageable, and we saw low rates of cytokine release syndrome and neurotoxicity... manageable to the extent that we are now thinking [forward to] outpatient settings. Response rates were high, but we did not see a plateauing of responses in very late-stage multiple myeloma.”

 

 
Jenny A
About the Author

Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
AmazonSmile
 

MORE MYELOMA CROWD NEWS

Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies